Subscribe
merck-be-well-logo-2
Copyright © 2009-2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.
21 September 2016Americas

Sanofi sues Merck over Lantus patents

Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus (insulin glargine injection) and Lantus SoloSTAR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?